Silvana Lanzalone

2.5k total citations · 2 hit papers
35 papers, 1.9k citations indexed

About

Silvana Lanzalone is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Genetics. According to data from OpenAlex, Silvana Lanzalone has authored 35 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 29 papers in Oncology, 25 papers in Pulmonary and Respiratory Medicine and 9 papers in Genetics. Recurrent topics in Silvana Lanzalone's work include PARP inhibition in cancer therapy (14 papers), Lung Cancer Treatments and Mutations (10 papers) and Advanced Breast Cancer Therapies (8 papers). Silvana Lanzalone is often cited by papers focused on PARP inhibition in cancer therapy (14 papers), Lung Cancer Treatments and Mutations (10 papers) and Advanced Breast Cancer Therapies (8 papers). Silvana Lanzalone collaborates with scholars based in Italy, United States and France. Silvana Lanzalone's co-authors include Éric Raymond, Ann‐Lii Cheng, María José Lechuga, Yoon‐Koo Kang, Liqiang Yang, Susan Pitman Lowenthal, Shukui Qin, Guido Poggi, Xiangqun Song and Joong‐Won Park and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and The Lancet Oncology.

In The Last Decade

Silvana Lanzalone

34 papers receiving 1.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Sunitinib Versus Sorafenib in Advanced Hepatocellular Cancer: Results of a Randomized Phase III Trial

2013 586 citations Ann‐Lii Cheng, Silvana Lanzalone et al. Journal of Clinical Oncology profile →
Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial

2020 252 citations Jennifer K. Litton, Sara A. Hurvitz et al. Annals of Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Silvana Lanzalone Italy	17	878	826	753	507	469	35	1.9k
Elisa Sensi Italy	20	1.5k 1.7×	423 0.5×	586 0.8×	609 1.2×	555 1.2×	44	2.3k
Cristiana Lupi Italy	18	1.7k 1.9×	421 0.5×	631 0.8×	708 1.4×	608 1.3×	35	2.8k
Sara Toffanin United States	14	515 0.6×	890 1.1×	266 0.4×	1.2k 2.3×	317 0.7×	18	2.3k
Shao-Chun Chang United States	7	1.2k 1.3×	676 0.8×	448 0.6×	637 1.3×	341 0.7×	7	2.2k
Zhong‐Zhe Lin Taiwan	22	740 0.8×	498 0.6×	552 0.7×	418 0.8×	224 0.5×	65	1.5k
Marta Schirripa Italy	23	1.4k 1.6×	404 0.5×	538 0.7×	489 1.0×	494 1.1×	125	1.9k
Giorgia Marisi Italy	23	478 0.5×	423 0.5×	233 0.3×	603 1.2×	230 0.5×	71	1.4k
Fortunato Ciardiello Italy	23	1.7k 1.9×	240 0.3×	697 0.9×	435 0.9×	537 1.1×	79	2.3k
Yu-Chien Chou United States	5	481 0.5×	241 0.3×	418 0.6×	445 0.9×	197 0.4×	5	1.1k
David J. Mauro United States	11	1.6k 1.8×	265 0.3×	755 1.0×	459 0.9×	451 1.0×	26	2.0k

Countries citing papers authored by Silvana Lanzalone

Since Specialization

Citations

This map shows the geographic impact of Silvana Lanzalone's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Silvana Lanzalone with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Silvana Lanzalone more than expected).

Fields of papers citing papers by Silvana Lanzalone

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Silvana Lanzalone. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Silvana Lanzalone. The network helps show where Silvana Lanzalone may publish in the future.

Co-authorship network of co-authors of Silvana Lanzalone

This figure shows the co-authorship network connecting the top 25 collaborators of Silvana Lanzalone. A scholar is included among the top collaborators of Silvana Lanzalone based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Silvana Lanzalone. Silvana Lanzalone is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Agarwal, Neeraj, Fred Saad, Arun Azad, et al.. (2023). TALAPRO-3 Clinical Trial Protocol: Phase III Study of Talazoparib Plus Enzalutamide in Metastatic Castration-Sensitive Prostate Cancer. Future Oncology. 20(9). 493–505. 19 indexed citations

Agarwal, Neeraj, Arun Azad, Karim Fizazi, et al.. (2022). Talapro-3: A phase 3, double-blind, randomized study of enzalutamide (ENZA) plus talazoparib (TALA) versus placebo plus enza in patients with DDR gene mutated metastatic castration-sensitive prostate cancer (mCSPC).. Journal of Clinical Oncology. 40(6_suppl). TPS221–TPS221. 20 indexed citations

Lee, Kyung-Hun, Joohyuk Sohn, Annabel Goodwin, et al.. (2021). Talazoparib Versus Chemotherapy in Patients with HER2-negative Advanced Breast Cancer and a Germline BRCA1/2 Mutation Enrolled in Asian Countries: Exploratory Subgroup Analysis of the Phase III EMBRACA Trial. Cancer Research and Treatment. 53(4). 1084–1095. 7 indexed citations

Martín, M., H. S. Rugo, Sara A. Hurvitz, et al.. (2021). 272P Outcomes of patients (pts) who had received prior platinum (PP) therapy in the phase III EMBRACA trial of talazoparib (TALA) vs physician’s choice of chemotherapy (PCT) in patients with germline BRCA1/2 mutated (gBRCA1/2mut) advanced breast cancer (ABC). Annals of Oncology. 32. S481–S481. 1 indexed citations

Agarwal, Neeraj, Arun Azad, Joaquı́n Mateo, et al.. (2021). 645TiP TALAPRO-3: A phase III, double-blind, randomized study of enzalutamide (ENZA) plus talazoparib (TALA) vs placebo plus ENZA in patients (pts) with DDR gene mutated metastatic castration-sensitive prostate cancer (mCSPC). Annals of Oncology. 32. S672–S673. 2 indexed citations

Litton, Jennifer K., Sara A. Hurvitz, Lida A. Mina, et al.. (2020). Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial. Annals of Oncology. 31(11). 1526–1535. 252 indexed citations breakdown →

Patel, Sandip Pravin, Suchita Pakkala, Nathan A. Pennell, et al.. (2020). Phase Ib Study of Crizotinib plus Pembrolizumab in Patients with Previously Untreated Advanced Non-Small Cell Lung Cancer with ALK Translocation. The Oncologist. 25(7). 562–e1012. 29 indexed citations

Soria, Jean‐Charles, Steffan N. Ho, Marileila Varella‐Garcia, et al.. (2018). Correlation of extent of ALK FISH positivity and crizotinib efficacy in three prospective studies of ALK-positive patients with non-small-cell lung cancer. Annals of Oncology. 29(9). 1964–1971. 12 indexed citations

Blackhall, Fiona, D. Ross Camidge, Alice T. Shaw, et al.. (2017). Final results of the large-scale multinational trial PROFILE 1005: efficacy and safety of crizotinib in previously treated patients with advanced/metastatic ALK-positive non-small-cell lung cancer. ESMO Open. 2(3). e000219–e000219. 82 indexed citations

10.

Tan, Weiwei, Keith D. Wilner, Silvana Lanzalone, et al.. (2015). Abstract CT117: Evaluation of the effect of crizotinib (CRZ) on the QT interval in patients with ALK-positive non-small cell lung cancer (NSCLC). Cancer Research. 75(15_Supplement). CT117–CT117. 1 indexed citations

11.

Kim, D., Myung‐Ju Ahn, Pan‐Chyr Yang, et al.. (2012). Updated Results of a Global Phase II Study with Crizotinib in Advanced Alk-Positive Non-Small Cell Lung Cancer (NSCLC). Annals of Oncology. 23. ix402–ix402. 57 indexed citations

12.

Harmon, Charles S., Samuel E. DePrimo, Éric Raymond, et al.. (2011). Mechanism-related circulating proteins as biomarkers for clinical outcome in patients with unresectable hepatocellular carcinoma receiving sunitinib. Journal of Translational Medicine. 9(1). 120–120. 19 indexed citations

13.

Reck, Martin, Norbert Frickhofen, S. Cedrés, et al.. (2010). Sunitinib in combination with gemcitabine plus cisplatin for advanced non-small cell lung cancer: A phase I dose-escalation study. Lung Cancer. 70(2). 180–187. 38 indexed citations

14.

Faivre, Sandrine, Éric Raymond, Éveline Boucher, et al.. (2009). Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open-label, multicentre, phase II study. The Lancet Oncology. 10(8). 794–800. 219 indexed citations

15.

Faivre, Sandrine, Éric Raymond, Jean‐Yves Douillard, et al.. (2007). Assessment of safety and drug-induced tumor necrosis with sunitinib in patients (pts) with unresectable hepatocellular carcinoma (HCC). Journal of Clinical Oncology. 25(18_suppl). 3546–3546. 49 indexed citations

16.

Reck, Martin, Norbert Frickhofen, U. Gatzemeier, et al.. (2007). P3-134: Sunitinib in combination with gemcitabine plus cisplatin for advanced non–small cell lung cancer (NSCLC): preliminary results from a phase I dose escalation study. Journal of Thoracic Oncology. 2(8). S736–S736. 1 indexed citations

17.

Faivre, Sandrine, Éric Raymond, Jean-Yves Douillard, et al.. (2007). 3535 POSTER Phase II trial investigating the efficacy and safety of sunitinib in patients with unresectable hepatocellular carcinoma (HCC). European Journal of Cancer Supplements. 5(4). 270–270. 4 indexed citations

18.

Reck, Martin, N. Frickhofen, U. Gatzemeier, et al.. (2007). 6607 POSTER Preliminary findings of a phase I dose-escalation study of sunitinib in combination with gemcitabine plus cisplatin in advanced non-small cell lung cancer (NSCLC). European Journal of Cancer Supplements. 5(4). 390–390.

19.

Paridaens, Robert, José Thomas, J. Wildiers, et al.. (1998). Safety, activity and estrogen inhibition by exemestane in postmenopausal women with advanced breast cancer: a phase I study. Anti-Cancer Drugs. 9(8). 675–683. 36 indexed citations

20.

Thürlimann, Beat, R. Paridaens, D. Serin, et al.. (1997). Third-line hormonal treatment with exemestane in postmenopausal patients with advanced breast cancer progressing on aminoglutethimide: a phase ii multicentre multinational study. European Journal of Cancer. 33(11). 1767–1773. 119 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact